HC Berlin Pharma AG
HC Berlin Pharma AG obtains subsidies from the Federal State of Brandenburg for setting up productions facilities
HC Berlin Pharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Berlin, November 27, 2008 – HC Berlin Pharma AG, a company listed on the Open Market of the Frankfurt Stock Exchange, today announced that they would obtain public subsidies from the Federal State of Brandenburg for the construction of production facilities and laboratories at the company’s new research and development location at ’Wissenschaftspark Golm’ in Potsdam. The Minister of Economic Affairs of the Federal State of Brandenburg, Mr. Ulrich Junghanns, personally promised the support. After the establishment of a research laboratory, the first portion of the funds in the amount of approximately € 2m shall be applied to further pursue construction of preproduction, research and quality assurance laboratories. Furthermore, an overall investment of approximately € 33m shall include an investment in the industrial production facility for large-scale serial production in connection with research, quality assurance and logistics. ZukunftsAgentur Brandenburg (ZAB), the agency attending to the subsidies by order of the Federal State of Brandenburg, announced that approximately 45 % of the investment applied for by HC Berlin Pharma AG will be subsidized by the State. 'This is evidence that the Federal State of Brandenburg is convinced about our innovative products', Ottmar W. Geiger, CEO of HC Berlin Pharma AG states. 'We are especially glad about the support shown by State Minister Ulrich Junghanns who not only appreciates the importance of HC Berlin Pharma AG at ’Wissenschaftspark Potsdam-Golm’ with regard to jobs in the region but also emphasizes the scientific and international aspects of the Potsdam-Golm location', Rudolf W. Schötteldreier, Chairman of the Supervisory Board of HC Berlin Pharma AG, adds. The Federal State of Brandenburg provides subsidies to innovative enterprises in growth industries which intend to newly establish themselves or expand in the Federal State of Brandenburg. The State’s promotion policy is based on the principle: 'Enhancement of strengths'. Therefore, public funding focuses on growth centers like ‘Wissenschaftspark Potsdam-Golm’ with its connection to the university and to research institutes (Max-Planck Institute for Molecular Plant Physiology and Fraunhofer Institute for Applied Polymer Research). HC Berlin Pharma AG mainly specializes in the development and production of innovative pharmaceutical products. New pharmaceutical forms of already tried and tested substances which show higher efficiency and healing capacities in the relevant tests have been developed. The company mainly focuses on ArTiMist™, the drug against malaria, and NiCoSorb™ against nicotine addiction. The management of HC Berlin Pharma AG entrusted Pharma Consult Heidelberg (PhC) with the construction of the production facilities and gave its approval for the launch of the works. After an intensive planning phase, the establishment of the relevant facilities for quality control and research & development was approved as well. PhC as a partner of HC Berlin Pharma AG is responsible for the technical planning of the facilities and is developing strategies for optimizing the whole value creation process in consideration of the common rules of GMP (good manufacturing practice). Furthermore, PhC is helping to render processes and systems for the production of pharmaceutical products qualifiable and amenable to validation, and to set up an organizational structure. PhC’s expertise lies in the field of factory planning, and the company’s specialized knowledge of GMP principles has already been used by numerous internationally leading pharmaceutical enterprises like BayerSchering, Novartis or Pfizer. After completion of the facilities at ’Wissenschaftspark Potsdam-Golm’, ArTiMist™ and other preparations will be bottled there. ArTiMist™, an anti-malaria drug especially developed for children and administered as a sublingual spray is the company’s flagship product. ArTiMist™ has already successfully passed phase I of the clinical studies. The phase II toxicity test will not be required since the substance has already been admitted. ArTiMist™ is about to undergo the last clinical examination phase (phase III). Market admission has been planned for the year 2009. In 2005, the market potential for malaria treatments based on artemisinin was estimated at 220 million treatments by the WHO. HC Berlin Pharma AG is planning to satisfy about 5 % of the annual demand determined by the WHO. As regards the African and Asian markets 75 % of the 2009 demand, i.e. approximately 7.5 million units have already been secured through purchase agreements. Furthermore, HC Berlin Pharma AG instructed the securities trading bank Close Brothers Seydler Bank AG to act as a designated sponsor as of November 10, 2008 and to actively engage in market activities in order to promote the liquidity of the shares. Further information around HC Berlin Pharma AG can be found under www.hcberlinpharma.ag. For more detailed information please directly contact our Investor Relations Team: esVedra consulting GmbH t: +49. 89. 28 80 81 33 f: +49. 89. 28 80 81 49 info@esvedra-consulting.com www.esvedra-consulting.com About HC Berlin Pharma AG HC Berlin Pharma AG is a pharmaceutical company listed on the Open Market of the Frankfurt Stock Exchange, which develops and will manufacture pharmaceutical and medical technology solutions at its headquarter in Berlin. The company founded in May 2007 is developing new pharmaceutical forms of already tried and tested substances which guarantee higher efficiency and healing capacity. The flagship product of HC Berlin Pharma AG is ArTiMist™, a sublingual spray for malaria treatment, especially designed for infants and children. NiCoSorb™, a nicotine replacement therapy is another aerosol spray offered by HC Berlin Pharma AG. In the field of medical technology HC Berlin Pharma AG offers safe injection syringes, ClipOn™ and VetLok™, for human and veterinary medicine. HC Berlin Pharma AG is also marketing the brand MediSheet™, a sterile operation sheet for safe and germ-free operations and has also specialized in the production of tamper evident and childproof packaging for remedies. Disclaimer This release only serves general purposes and is by no means intended as an invitation to buy or sell shares of HC Berlin Pharma AG. 27.11.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found